An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Type Ⅱ diabetes mellitus * Between 18 years and 80 years old * The patient who has been taking oral hypoglycemic agent since 3 months with HbA1c 6.5 to 9% at screening test or who is drug naive or stopped taking oral hypoglycemic agent more then 3 months with HbA1c 7 to 10% at screening test * BMI between 21kg/㎡ and 40kg/㎡ * Diagnosis of type Ⅱ diabetes before 3 months * C-peptide level is over 1.0 ng/ml * Condition for female having contraception methods, surgical sterilization or menopause * Condition for male agreeing to use of recommendatory and appropriate contraception method * Agreement with written informed consent Exclusion Criteria: * Type I diabetes, gestational diabetes or secondary diabetes * Treatment with insulin or thiazolidinediones within 60 days * Fasting Plasma Glucose level is over 250 mg/dl * Triglyceride level is 500 mg/dl and over * Uncontrollable hypertension(Although treat with antihypertension agent, systolic blood pressure greater than 140 mmHg and diastolic blood pressure greater than 90 mmHg) * History of myocardial infarction, heart failure, cerebral infarction, hematencephalon or unstable angina within 6 months * Severe hepatic dysfunction: AST, ALT, Total bilirubin, ALP level over or equal to 2.5 times as high as upper normal limit(UNL) * Severe renal dysfunction: Renal failure or serum creatinine greater than 30% normal limit * Anemia for any reason * Needs treatment for acute disease, uncontrolled other diseae or diabetic complications * Abnormality of thyroid function(out of normal TSH range ) * History of proliferative diabetic retinopathy * In treatment concomitant drug having severe risk drug interaction with investigational drug * History of cancer within 5 years * History of drug abuse or alcoholism * Hepatitis B Antigen(HBsAg) test is positive * Treatment systemic or inhalant corticosteroids within 1 month prior to Screening * Patient who have experience such as hypersensitivity reaction, serious adverse event or no effect by treatment with glitazones * Fertile women who not practice contraception with appropriate methods * Pregnant women or nursing mothers * Has a contraindication to treatment investigational drug from the medical and psychogenic side * An impossible one who participates in clinical trial by legal or investigator's decision * Participated in other trial within 4 weeks * Participating in other trial at present